The 2018 accelerated approval of Vitrakvi was converted to full approval based on results from three trials in adult and pediatric patients.

The company expects early cohort data this year from the trial assessing the calpain-2-targeted antisense oligonucleotide therapy.

ACMG, NSGC, and others in the genetics community are monitoring whether the widely used online clinical genetics database ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

Cardinal is using its own cyclotron installations to produce Gozellix for distribution across a range of US locations.

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

BrainStorm has attempted to gain market approval for NurOwn without success but remains committed to developing the cell therapy.

The recommendation was based on results from the Phase III THOR trial, which compared Balversa to chemotherapy.

On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...

NEW YORK – Singapore's Experimental Drug Development Center (EDCC) will use Engine Biosciences' machine-learning platform to advance precision cancer therapies, according to a partnership announced ...

The approval was based on results from a Phase III trial showing that Opdivo-Yervoy improved outcomes against Opdivo alone and chemo alone.

The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.